Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$57.05 USD

57.05
3,395,231

0.00 (0.00%)

Updated May 15, 2024 04:00 PM ET

After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.

AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS

AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.

Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance

Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.

AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label

AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.

Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Incyte (INCY) Q3 Earnings and Revenues Beat Estimates

Incyte (INCY) delivered earnings and revenue surprises of 55.26% and 8.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Incyte Corporation (INCY) Ahead of Earnings?

Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?

Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Incyte (INCY)

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment

Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD

Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.

Ekta Bagri headshot

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis

Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.

AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.

AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq

FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.